Health Canada Approves Needle-Free Epinephrine Nasal Spray Neffy for Severe Allergic Reactions
Health Canada has approved Neffy, the first needle-free epinephrine treatment for severe allergic reactions, as a nasal spray. ALK Canada purchased rights to distribute the two-milligram dose for adults and children weighing at least 30 kilograms. The product could reach the market this summer.
cbsnews.comApproval of Neffy in Canada Health Canada approved Neffy, the first needle-free epinephrine treatment for severe allergic reactions, on April 15, 2026.
The approval covers a nasal spray version of the drug. ALK Canada purchased the rights to distribute Neffy in the country. The Neffy treatment consists of a two-milligram dose approved for adults and pediatric patients who weigh at least 30 kilograms.
That weight is roughly 66 pounds. The product is pocket-sized and has a shelf life of 30 months from its time of manufacture. ALK Canada stated the Neffy spray could be on the market as soon as this summer.
U.S. Approval and Dosage Details Neffy was approved for use in the United States in summer 2024.
In the United States, Neffy is available in a one-milligram dose for kids who weigh 15 to 30 kilograms. The one-milligram dose of Neffy has not been approved in Canada.
Current Treatment Options Epinephrine auto-injectors known by the brand name EpiPen are the only emergency treatment option available for allergic reactions.
EpiPens are single-use, pre-filled devices used to shoot a dose of epinephrine into the muscle.
Response from Advocacy Group Food Allergy Canada, a Toronto-based non-profit organization, applauded the approval of the two-milligram Neffy treatment as 'an important step forward' that gives Canadians more choices.
Story Timeline
3 events- 2026-04-15
Health Canada approves two-milligram Neffy nasal spray for adults and pediatric patients weighing at least 30 kilograms.
1 sourceHealth Canada - 2026 (pre-approval)
ALK Canada purchases rights to distribute Neffy.
1 sourceALK Canada - Summer 2024
Neffy approved for use in the United States, including one-milligram dose for kids weighing 15 to 30 kilograms.
1 sourceunattributed
Potential Impact
- 01
Non-approval of one-milligram dose limits options for lighter pediatric patients in Canada.
- 02
Canadians gain alternative to EpiPen for severe allergic reactions, potentially improving access for those fearing needles.
- 03
Shift from injectors to nasal sprays could reduce barriers to emergency use in public settings.
- 04
Market entry of Neffy this summer could increase treatment options for adults and heavier children.
- 05
Advocacy groups like Food Allergy Canada may push for broader approvals, enhancing overall allergy management.
Transparency Panel
Related Stories
Sebastian Ballard / Wikimedia (CC BY-SA 2.0)Hospital Admissions for Spider Bites Increase in England Over Past Decade
NHS figures show hospital admissions linked to spider bites in England rose from 47 in 2015 to 100 in 2025. Experts attribute the trend to the growing population of noble false widow spiders. The spiders are not aggressive and have not caused serious illness or death, though bite…
StatFDA Sends Reminder Letters to Over 2,200 Companies and Researchers on Clinical Trial Reporting
The Food and Drug Administration sent reminder letters to more than 2,200 companies and researchers, informing them of the requirement to report clinical trial results to a federal database or face fines. The letters target entities associated with over 3,000 registered trials, s…
StatSTAT Publishes Reader Responses on Nutrition Education and Emergency Room Challenges in Healthcare
STAT News featured letters to the editor responding to articles on nutrition education in medical schools and emergency room conditions. Contributors addressed social determinants of health, the need for interdisciplinary collaboration, and risks to vulnerable patients in ER hall…